A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity

Even-Or, Orli; Joseph, Aviva; Itskovitz-Cooper, Noga; Samira, Sarit; Rochlin, Eli; Eliyahu, Hagit; Goldwaser, Itzik; Balasingam, Shobana; Mann, Alex; Lambkin‐Williams, Robert

doi:10.1016/j.vaccine.2011.01.009

Cited by 34 publications

(20 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following viral challenge, the vaccine reduced the severity of infection. Biodistribution studies showed that lipids and antigens are retained in nose and lung, increasing cytokine levels and expression of costimulatory molecules [Even-Or et al 2011]. Chen and colleagues developed a cationic lipopolymer, the liposome-polyethyleneglycol-polyethyleneimine complex (LPPC) adjuvant for surface adsorption of antigens or immunomodulators.…”

Section: Other Cationic Lipid Complexesmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

440

309

View full text Add to dashboard Cite

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly increased. A key advantage of liposomes, archaeosomes and virosomes in general, and liposome-based vaccine delivery systems in particular, is their versatility and plasticity. Liposome composition and preparation can be chosen to achieve desired features such as selection of lipid, charge, size, size distribution, entrapment and location of antigens or adjuvants. Depending on the chemical properties, water-soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped within the aqueous inner space of liposomes, whereas lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants can be attached to the liposome surface either by adsorption or stable chemical linking. Coformulations containing different types of antigens or adjuvants can be combined with the parameters mentioned to tailor liposomal vaccines for individual applications. Special emphasis is given in this review to cationic adjuvant liposome vaccine formulations. Examples of vaccines made with CAF01, an adjuvant composed of the synthetic immune-stimulating mycobacterial cordfactor glycolipid trehalose dibehenate as immunomodulator and the cationic membrane forming molecule dimethyl dioctadecylammonium are presented. Other vaccines such as cationic liposome-DNA complexes (CLDCs) and other adjuvants like muramyl dipeptide, monophosphoryl lipid A and listeriolysin O are mentioned as well. The field of liposomes and liposome-based vaccines is vast. Therefore, this review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines. Studies on liposome-based veterinary vaccines and experimental therapeutic cancer vaccines are also summarized.

show abstract

Section: Other Cationic Lipid Complexesmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

440

309

View full text Add to dashboard Cite

show abstract

“…One reason for this long gap is that the principles of adjuvant activity were largely unknown; thus, the development of adjuvants was empirical, Moreover, many adjuvants, including Freund's adjuvant, were reactogenic and not acceptable for licensure (2). Recent methods to improve vaccine delivery have taken several approaches, including the use of virosomes (3)(4)(5), vector-based methods (6)(7)(8), liposome-based methods (9)(10)(11), and the use of more traditional formulation with adjuvants (12)(13)(14)(15)(16)(17). Each of these methods has some drawbacks, in terms of reactogenicity, regulatory issues, product stability, or time required for formulation; however, each of these methods focuses on presenting the vaccine as a particulate.…”

mentioning

confidence: 99%

Vaccine Self-Assembling Immune Matrix Is a New Delivery Platform That Enhances Immune Responses to Recombinant HBsAg in Mice

Grenfell

Shollenberger

Samli

et al. 2015

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

bVaccination remains the most effective public health tool to prevent infectious diseases. Many vaccines are marginally effective and need enhancement for immunocompromised, elderly, and very young populations. To enhance immunogenicity, we exploited the biphasic property of the (RADA)4 synthetic oligopeptide to create VacSIM (vaccine self-assembling immune matrix), a new delivery method. VacSIM solution can easily be mixed with antigens, organisms, and adjuvants for injection. Postinjection, the peptides self-assemble into hydrated nanofiber gel matrices, forming a depot with antigens and adjuvants in the aqueous phase. We believe the depot provides slow release of immunogens, leading to increased activation of antigen-presenting cells that then drive enhanced immunogenicity. Using recombinant hepatitis B virus surface antigen (rHBsAg) as a model immunogen, we compared VacSIM delivery to delivery in alum or complete Freund's adjuvant (CFA). Delivery of the rHBsAg antigen to mice via VacSIM without adjuvant elicited higher specific IgG responses than when rHBsAg was delivered in alum or CFA. Evaluating IgG subtypes showed a mixed Th1/Th2 type response following immunization with VacSIM, which was driven further toward Th1 with addition of CpG as the adjuvant. Increased specific IgG endpoint titers were observed in both C57BL/6 and BALB/c mice, representative of Th1 and Th2 environments, respectively. Restimulation of splenocytes suggests that VacSIM does not cause an immediate proinflammatory response in the host. Overall, these results suggest that VacSIM, as a new delivery method, has the potential to enhance immunogenicity and efficacy of numerous vaccines. Vaccines remain the single greatest public health tool to combat infectious diseases. Vaccine formulation and delivery are key to the ability of vaccines to induce the desired immune responses. One goal of vaccine delivery is to present vaccine antigens in a manner that enhances antigen-presenting-cell (APC) activation, leading to antigen/organism uptake and processing of vaccine antigen(s). Delivery methods or adjuvants that safely enhance vaccine immunogenicity/efficacy are desirable for vaccines that are marginally effective and for vaccines administered to low responders or immunocompromised populations. Additional goals are to reduce the number of doses required to induce effective, vaccine responses and to reduce the amount of vaccine/dose, especially when a single dose of vaccine is administered, as with annual influenza vaccines. Lastly, in pandemics, a vaccine that produces high titers after a single administration would be beneficial. Recent advances in the understanding of how innate mechanisms influence adaptive immunity have led to more rational design in the development of new vaccine adjuvants and delivery systems.Aluminum salts were the first adjuvants licensed for human vaccines in the 1920s. The licensure of non-aluminum salt adjuvants took an additional 80 years (1). One reason for this long gap is that the principles of adjuvant activit...

show abstract

“…This may be attributed to the reduction in antigen transport to the draining lymph nodes [51]. At present, as reported previously [38], at least 8 antigen containg liposomebased adjuvant systems are endorsed for human use or are under clinical trials stage (Table 1) [52][53][54][55][56][57][58][59][60][61][62][63][64].…”

Section: Liposome As Mucosal Vaccine Delivery Systemmentioning

confidence: 82%

Nanocarriers: a Versatile Approach for Mucosal Vaccine Delivery

et al. 2015

View full text Add to dashboard Cite

Infectious agents generally use mucosal surfaces as entry port to the body thereby necessitating the need of development of mucosal vaccine as vaccination is important for disease avoidance and suppression. Vaccination through mucosal route is a promising strategy to elicit efficient immune response as parentally administered vaccines induce poor mucosal immunity in general. Safety, economy and stability are highly desired with vaccines and this can be achieved with use of delivery cargos. This review focuses on challenges related with mucosal vaccines and use of nanocarriers as suitable cargos to cater the antigen effectively to the desired site. The review also includes different factors which are to be considered regarding the performance of the nanocarriers and clinical status of these systems.

show abstract

A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity

Cited by 34 publications

References 47 publications

Liposomes as vaccine delivery systems: a review of the recent advances

Liposomes as vaccine delivery systems: a review of the recent advances

Vaccine Self-Assembling Immune Matrix Is a New Delivery Platform That Enhances Immune Responses to Recombinant HBsAg in Mice

Nanocarriers: a Versatile Approach for Mucosal Vaccine Delivery

Contact Info

Product

Resources

About